Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 37

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations

Tang, Yigang, Song, Huaxin, Wang, Zhengyuan, Xiao, Shujun, Xiang, Xinrong, Zhan, Huien, Wu, Lili, Wu, Jiale, Xing, Yangfei, Tan, Yun, Liang, Ying, Yan, Ni, Li, Yuntong, Li, Jiabing, Wu, Jiaqi, Zheng, Derun, Jia, Yunchuan, Chen, Zhiming, Li, Yunqi, Zhang, Qianqian, Zhang, Jianming, Zeng, Hui, Tao, Wei, Liu, Feng, Wu, Yu, Lu, Min·2022·Cell Reports
DOI 10.1016/j.celrep.2022.110622
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2022.110622

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 68

  1. Alexandrova, 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment, Nature, 523, 352, 10.1038/nature14430 · DOI · Paper page
  2. Arbely, 2011, Acetylation of lysine 120 of p53 endows DNA-binding specificity at effective physiological salt concentration, Proc. Natl. Acad. Sci. U S A., 108, 8251, 10.1073/pnas.1105028108 · DOI
  3. Baiocco, 2009, Molecular basis of antimony treatment in leishmaniasis, J. Med. Chem., 52, 2603, 10.1021/jm900185q · DOI · Paper page
  4. Bauer, 2016, 2-Sulfonylpyrimidines: mild alkylating agents with anticancer activity toward p53-compromised cells, Proc. Natl. Acad. Sci. U S A., 113, E5271, 10.1073/pnas.1610421113 · DOI
  5. Bullock, 2001, Rescuing the function of mutant p53, Nat. Rev. Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
  6. Bullock, 2000, Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
  7. Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov., 2, 401, 10.1158/2159-8290.CD-12-0095 · DOI · Paper page
  8. Chakravarty, 2017, OncoKB: a precision oncology knowledge base, JCO Precis. Oncol., 1, 1, 10.1200/PO.17.00011 · DOI · Paper page
  9. Chen, 2013, Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool, BMC Bioinformatics, 14, 128, 10.1186/1471-2105-14-128 · DOI · Paper page
  10. Chen, 2021, Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site, Cancer Cell, 39, 225, 10.1016/j.ccell.2020.11.013 · DOI · Paper page
  11. Cluzeau, 2021, Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM), J. Clin. Oncol., 39, 1575, 10.1200/JCO.20.02342 · DOI · Paper page
  12. Demma, 2010, SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53, J. Biol. Chem., 285, 10198, 10.1074/jbc.M109.083469 · DOI
  13. Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics (Oxford, England), 29, 15
  14. Dumble, 2021, Abstract LB006: PC14586: the first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development, Cancer Res., 81, LB006, 10.1158/1538-7445.AM2021-LB006 · DOI · Paper page
  15. Emsley, 2004, Coot: model-building tools for molecular graphics, Acta Crystallogr. Section D Biol. Crystallogr., 60, 2126, 10.1107/S0907444904019158 · DOI · Paper page
  16. Feng, 2012, GFOLD: a generalized fold change for ranking differentially expressed genes from RNA-seq data, Bioinformatics (Oxford, England), 28, 2782
  17. Fischer, 2017, Census and evaluation of p53 target genes, Oncogene, 36, 3943, 10.1038/onc.2016.502 · DOI · Paper page
  18. Frézard, 2014, Antimony transport mechanisms in resistant leishmania parasites, Biophys. Rev., 6, 119, 10.1007/s12551-013-0134-y · DOI
  19. Frézard, 2012, Greater binding affinity of trivalent antimony to a CCCH zinc finger domain compared to a CCHC domain of kinetoplastid proteins, Metallomics, 4, 433, 10.1039/c2mt00176d · doi:10.1039/c2mt00176d
  20. Gaiddon, 2001, A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain, Mol. Cell Biol., 21, 1874, 10.1128/MCB.21.5.1874-1887.2001 · DOI · Paper page
  21. Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal., 6, pl1, 10.1126/scisignal.2004088 · DOI · Paper page
  22. Ghosh, 2019, Covalent inhibition in drug discovery, ChemMedChem, 14, 889, 10.1002/cmdc.201900107 · DOI · Paper page
  23. Gummlich, 2021, ATO stabilizes structural p53 mutants, Nat. Rev. Cancer, 21, 141, 10.1038/s41568-021-00337-1 · doi:10.1038/s41568-021-00337-1
  24. Hao, 2020, Integrated analysis of multimodal single-cell data, bioRxiv
  25. Hirano, 1995, A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down, Oncogene, 10, 1879
  26. Jagosova, 2012, Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells, Int. J. Oncol., 41, 1157, 10.3892/ijo.2012.1520 · DOI
  27. Jaser, 1995, Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis, Pharm. Res., 12, 113, 10.1023/A:1016251023427 · doi:10.1023/a:1016251023427
  28. Jia, 1997, Screening the p53 status of human cell lines using a yeast functional assay, Mol. Carcinog., 19, 243, 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D · doi:10.1002/(sici)1098-2744(199708)19:4<243::aid-mc5>3.0.co;2-d
  29. Joerger, 2006, Structural basis for understanding oncogenic p53 mutations and designing rescue drugs, Proc. Natl. Acad. Sci. U S A., 103, 15056, 10.1073/pnas.0607286103 · DOI · Paper page
  30. Joerger, 2007, Structure-function-rescue: the diverse nature of common p53 cancer mutants, Oncogene, 26, 2226, 10.1038/sj.onc.1210291 · DOI · Paper page
  31. Joerger, 2016, The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches, Annu. Rev. Biochem., 85, 375, 10.1146/annurev-biochem-060815-014710 · DOI · Paper page
  32. Kabsch, 2010, XDS, Acta Crystallogr. D Biol Crystallogr., 66, 125, 10.1107/S0907444909047337 · DOI · Paper page
  33. Kandoth, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634 · DOI · Paper page
  34. Kotler, 2018, A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation, Mol. Cell, 71, 178, 10.1016/j.molcel.2018.06.012 · DOI · Paper page
  35. Kumar, 2012, Immunobiology of visceral leishmaniasis, Front Immunol., 3, 251, 10.3389/fimmu.2012.00251 · DOI · Paper page
  36. Lane, 1992, Cancer. p53, guardian of the genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
  37. Lee, 2012, Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo, Cancer Cell, 22, 751, 10.1016/j.ccr.2012.10.022 · DOI
  38. Li, 2011, SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis, Cell Death Differ., 18, 1904, 10.1038/cdd.2011.71 · DOI · Paper page
  39. Loh, 2021, Arsenic and an old place: rescuing p53 mutants in cancer, Cancer cell, 39, 140, 10.1016/j.ccell.2021.01.012 · DOI · Paper page
  40. Martin, 2011, Cutadapt removes adapter sequences from high-throughput sequencing reads, EMBnet. J., 17, 3, 10.14806/ej.17.1.200 · DOI · Paper page
  41. Martínez-Jiménez, 2020, A compendium of mutational cancer driver genes, Nat. Rev. Cancer, 20, 555, 10.1038/s41568-020-0290-x · DOI · Paper page
  42. McCoy, 2007, Phaser crystallographic software, J. Appl. Crystallogr., 40, 658, 10.1107/S0021889807021206 · DOI · Paper page
  43. Muller, 2013, p53 mutations in cancer, Nat. Cel. Biol., 15, 2, 10.1038/ncb2641 · DOI · Paper page
  44. Potterton, 2003, A graphical user interface to the CCP4 program suite, Acta Crystallogr. Section D Biol. Crystallogr., 59, 1131, 10.1107/S0907444903008126 · DOI · Paper page
  45. Prasad, 2016, Perspective: the precision-oncology illusion, Nature, 537, S63, 10.1038/537S63a · DOI · Paper page
  46. Salim, 2016, COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K/AKT/mTOR pathway, Eur. J. Cancer, 69, S19, 10.1016/S0959-8049(16)32638-7 · DOI
  47. Shapiro, 2015, A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors, J. Clin. Oncol., 33, TPS2613, 10.1200/jco.2015.33.15_suppl.tps2613 · doi:10.1200/jco.2015.33.15_suppl.tps2613
  48. Singh, 2014, The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India, Parasit Vectors, 7, 596, 10.1186/s13071-014-0596-1 · doi:10.1186/s13071-014-0596-1
  49. Stein, 2019, Gain-of-Function mutant p53: all the roads lead to tumorigenesis, Int. J. Mol. Sci., 20, 6197, 10.3390/ijms20246197 · DOI · Paper page
  50. Stindt, 2015, Functional interplay between MDM2, p63/p73 and mutant p53, Oncogene, 34, 4300, 10.1038/onc.2014.359 · DOI
  51. Tannock, 2016, Limits to personalized cancer medicine, N. Engl. J. Med., 375, 1289, 10.1056/NEJMsb1607705 · DOI · Paper page
  52. Tovar, 2013, MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models, Cancer Res., 73, 2587, 10.1158/0008-5472.CAN-12-2807 · DOI · Paper page
  53. Vagin, 2004, REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use, Acta Crystallogr. Section D, Biol. Crystallogr., 60, 2184, 10.1107/S0907444904023510 · DOI · Paper page
  54. van Montfort, 2017, Structure-based drug design: aiming for a perfect fit, Essays Biochem., 61, 431, 10.1042/EBC20170052 · DOI
  55. Vogelstein, 2000, Surfing the p53 network, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
  56. Wallace, 1995, LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions, Protein Eng., 8, 127, 10.1093/protein/8.2.127 · DOI · Paper page
  57. Wang, 2001, The 'wildtype' conformation of p53: epitope mapping using hybrid proteins, Oncogene, 20, 2318, 10.1038/sj.onc.1204316 · DOI
  58. Wang, 2010, STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer, Curr. Opin. Investig. Drugs, 11, 1466
  59. Wassman, 2013, Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53, Nat. Commun., 4, 1407, 10.1038/ncomms2361 · DOI · Paper page
  60. Williams, 2018, MolProbity: more and better reference data for improved all-atom structure validation, Protein Sci. a Publ. Protein Soc., 27, 293, 10.1002/pro.3330 · DOI · Paper page
  61. Wu, 2021, Three optimized assays for the evaluation of compounds that can rescue p53 mutants, STAR Protoc., 2, 100688, 10.1016/j.xpro.2021.100688 · DOI
  62. Wu, 2021, Broad-spectrum rescue compounds for structural p53 mutations: perspective on 'Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site', J. Mol. Cell Biol., 13, 155, 10.1093/jmcb/mjab007 · DOI
  63. Yang, 2019, Integrity of zinc finger motifs in PML protein is necessary for inducing its degradation by antimony, Metallomics, 11, 1419, 10.1039/c9mt00102f · doi:10.1039/c9mt00102f
  64. Yu, 2021, Physical networks from entropy-driven non-covalent interactions, Nat. Commun., 12, 746, 10.1038/s41467-021-21024-7 · DOI
  65. Yu, 2012, Allele-specific p53 mutant reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
  66. Zaghloul, 2010, Clinical efficacy and pharmacokinetics of antimony in cutaneous leishmaniasis patients treated with sodium stibogluconate, J. Clin. Pharmacol., 50, 1230, 10.1177/0091270009347674 · doi:10.1177/0091270009347674
  67. Zhang, 2018, APR-246 reactivates mutant p53 by targeting cysteines 124 and 277, Cell Death Dis., 9, 439, 10.1038/s41419-018-0463-7 · DOI · Paper page
  68. Zhang, 1994, A temperature-sensitive mutant of human p53, EMBO J., 13, 2535, 10.1002/j.1460-2075.1994.tb06543.x · DOI

Cited by

See all 37

Metadata

Authors
Tang, Y., Song, H., Wang, Z., Xiao, S., Xiang, X., Zhan, H., Wu, L., Wu, J., Xing, Y., Tan, Y., Liang, Y., Yan, N., Li, Y., Li, J., Wu, J., Zheng, D., Jia, Y., Chen, Z., Li, Y., Zhang, Q., Zhang, J., Zeng, H., Tao, W., Liu, F., Wu, Y., & Lu, M.
ORCID
Venue
Cell Reports
Publisher
Elsevier BV
Published
2022-04
Volume
39
Issue
2
Pages
110622
ISSN
2211-1247
DOI
10.1016/j.celrep.2022.110622
Cited by
37
References
19
Language
en
Licence
Funders
  • National Key Research and Development Program of China (2017YFA0506200)
  • Science and Technology Commission of Shanghai Municipality (21S11900100)
  • Shanghai Jiao Tong University (20210104)
  • National Natural Science Foundation of China (81900157, 82073292, 82102756, 82130075)
  • Shanghai Municipal Education Commission (21SG18)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations. https://app.cochat.ai/papers/10.1016/j.celrep.2022.110622
The paper
Tang, Y., Song, H., Wang, Z., Xiao, S., Xiang, X., Zhan, H., Wu, L., Wu, J., Xing, Y., Tan, Y., Liang, Y., Yan, N., Li, Y., Li, J., Wu, J., Zheng, D., Jia, Y., Chen, Z., Li, Y., . . . Lu, M. (2022). Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations. Cell Reports. https://doi.org/10.1016/j.celrep.2022.110622

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.